A Phase 1/2 interventional study of pemetrexed and cisplatin in Non-Small-Cell Lung Cancer, sponsored by Eli Lilly and Company. Completed at 11 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-11-27.
Sponsored by Eli Lilly and Company · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 213 studies testing cisplatin in Carcinoma, Non-Small-Cell Lung — 13 open to participants now, 20 under way, 8 of them phase 3. Cisplatin · Carcinoma, Non-Small-Cell Lung.
Among the 213 studies testing cisplatin in Carcinoma, Non-Small-Cell Lung, this one is the 58th largest by enrollment of the 198 interventional ones that give a count, is one of 11 that started in 2007, is one of 16 in phase 1/2, and was the 79th registered.
7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.
Browse Carcinoma, Non-Small-Cell Lung studies →13 of the 213 studies testing cisplatin in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:
AstraZeneca · Sites in United States, Belgium, Brazil and 17 more countries
Ages 18+
The Affiliated Hospital of Qingdao University · Sites in China
Ages 18–75
AstraZeneca · Sites in United States, Belgium, Canada and 9 more countries
Ages 18–95
Hunan Province Tumor Hospital · Sites in China
Ages 18+
University Health Network, Toronto · Sites in Canada
Ages 18+
By country, each count listing its studies:
Cisplatin: first FDA approval 1978 (PLATINOL-AQ). What it is approved for, and how studies give it, is on its page →
Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
213 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 45 · Phase 2 132 · Phase 3 47 · Phase 4 3
First in 1994; this study’s year is marked. 11 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 120 is above the median of 62 across 6,024 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.
Median enrollment 58 across the 198 interventional studies. Of the 159 that completed or were terminated, 62 (39%) have results posted.
This tab as a report to print or save as PDF → With an account.
63 of 213 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
147 studies in Carcinoma, Non-Small-Cell Lung by Eli Lilly and Company: 6 open now, 20 under way, 6 of them phase 3. Of 121 finished, 81 (67%) have results posted.
Among the 147 studies in Carcinoma, Non-Small-Cell Lung by Eli Lilly and Company, this one is the 63rd largest by enrollment of the 139 interventional ones that give a count, is one of 9 that started in 2007, is one of 13 in phase 1/2, and was the 49th registered.
Eli Lilly and Company’s Carcinoma, Non-Small-Cell Lung studies by the year they started, since 2000.
4 of the studies testing cisplatin in Carcinoma, Non-Small-Cell Lung that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04585490Phase 3Stanford UniversityAdaptive ctDNA-Based Personalization of Treatment During Consolidation Therapy in NSCLC | 2026-12 |
| NCT06417814Phase 3AstraZenecaA Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer | 2027-01-11 |
| NCT02889666Shanghai Jiao Tong University School of MedicineA Randomised Trial of Chemotherapy Plus Surgery for Recurrent Non-Small Cell Lung Cancer | 2026-12 |
| NCT04253964Wake Forest University Health SciencesPilot Study of Performance Status 2 vs. Performance Status 0-1 Non-small Cell Lung Cancer Patients Treated With Chemo/Immunotherapy | 2027-09-01 |
Add all 4 to your calendar (.ics) → With an account.
Among the 213 studies testing cisplatin in Carcinoma, Non-Small-Cell Lung, from their registry updates:
Among Eli Lilly and Company’s 147 in Carcinoma, Non-Small-Cell Lung:
This tab as a report to print or save as PDF → With an account.
The primary purpose of this study is to determine the 2-year survival rate of both of the chemotherapy regimens in patients with inoperable non-small-cell lung cancer.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Pemetrexed + Carboplatin
Drug: pemetrexed · Drug: carboplatin · Radiation: radiation therapy
Pemetrexed + Cisplatin
Drug: pemetrexed · Drug: cisplatin · Radiation: radiation therapy
Phase 1 - 500 milligram/meter squared (mg/m²), administered intravenously, every 21 days for 3 cycles Phase 2 - 500 mg/m², administered intravenously, every 21 days for 3 cycles Consolidation Therapy - 500 mg/m² pemetrexed, administered intravenously, every 21 days for 3 cycles beginning 3 weeks after completion of chemoradiation therapy for each phase
Also known as: LY231514, Alimta
Phase 1 - 30 mg/m² and 75 mg/m², administered intravenously, Days 1, 8, 22, 29 and 43 Phase 2 - 75 mg/m², administered intravenously, every 21 days for 3 cycles
Phase 1 - dosed at area under the curve (AUC) 2 milligram/milliliter\*minute (mg/mL\*min), administered intravenously, Days 1, 8, 22, 29 and 43 Phase 2 - dosed at AUC 5 mg/mL\*min, administered intravenously, every 21 days for 3 cycles
Phase 1 - 2 Gray, daily, 5 days a week for Days 1-51 Phase 2 - 2 Gray, daily, 5 days a week for Days 1-45
Phase 1 - Maximum Tolerated Dose (MTD) of Carboplatin
MTD was defined as a dose at which the occurrence of at least 2 dose-limiting toxicities (DLTs) was observed. DLT was defined as any of the following events occurring during the entire radiation therapy (RT) course, including a 2-week recovery period following completion of RT: Grade 4 neutropenia (\<0.5 x 10\^9 cells per liter) lasting \>7 days, febrile neutropenia; ≥Grade 3 neutropenia with fever \>38.5 degrees Celsius (°C), Grade 4 thrombocytopenia, Grade 3 thrombocytopenia with ≥Grade 2 bleeding, ≥Grade 3 nonhematologic toxicity (excluding nausea, vomiting, and transaminase elevations) and ≥Grade 3 pulmonary or esophageal toxicity (radiation-related pneumonitis or esophagitis).
Time frame: Phase 1 enrollment to the end of study treatment up to Week 11
Phase 1 - Maximum Tolerated Dose (MTD) of Cisplatin
MTD was defined as a dose at which the occurrence of at least 2 dose-limiting toxicities (DLTs) was observed. DLT was defined as any of the following events occurring during the entire radiation therapy (RT) course, including a 2-week recovery period following completion of RT: Grade 4 neutropenia (\<0.5 x 10\^9 cells per liter) lasting \>7 days, febrile neutropenia; ≥Grade 3 neutropenia with fever \>38.5 degrees Celsius (°C), Grade 4 thrombocytopenia, Grade 3 thrombocytopenia with ≥Grade 2 bleeding, ≥Grade 3 nonhematologic toxicity (excluding nausea, vomiting, and transaminase elevations) and ≥Grade 3 pulmonary or esophageal toxicity (radiation-related pneumonitis or esophagitis).
Time frame: Phase 1 enrollment to the end of study treatment up to Week 11
Phase 2 - Survival Probability at 2 Years
Time frame: Phase 2 randomization up to 2 years
Phase 1 - Pharmacology Toxicity: Number of Participants With Dose Limiting Toxicities (DLTs)
Phase 1 pharmacology toxicity was defined as the number of participants experiencing dose limiting toxicities (DLTs). DLT was defined as any of the following events occurring during the entire radiation therapy (RT) course: Grade 4 neutropenia (\<0.5 x 10\^9 cells per liter) \>7 days, febrile neutropenia, ≥Grade 3 neutropenia with fever \>38.5 degrees Celsius (°C), Grade 4 thrombocytopenia, Grade 3 thrombocytopenia with ≥Grade 2 bleeding, ≥Grade 3 nonhematologic toxicity (excluding nausea, vomiting, and transaminase elevations), and ≥Grade 3 pulmonary or esophageal toxicity (radiation-related pneumonitis or esophagitis). Grade 5 events are the events leading to the death.
Time frame: Phase 1 enrollment up to Week 11
Phase 1 - Percentage of Participants With Complete Response or Partial Response (Response Rate)
Response rate is the percentage of participants with complete response (CR) or partial response (PR), as assessed according to the Response Evaluation Criteria In Solid Tumors (RECIST) guidelines. CR is disappearance of all target and non-target lesions; PR is ≥30% decrease in sum of longest diameter of target lesions. Response rate is calculated as a total number of participants with CR or PR divided by the total number of participants treated multiplied by 100.
Time frame: Phase 1 enrollment to the end of the study treatment up to Week 11
Phase 2 - Pharmacology Toxicity: Number of Participants With Adverse Events
Phase 2 pharmacology toxicity was defined as the number of participants who experienced serious adverse events or all other nonserious adverse events during the study. A summary of serious adverse events and other nonserious adverse events is located in the Reported Adverse Events section.
Time frame: Phase 2 randomization to the end of the study treatment up to 30.0 months
Phase 2 - Time to Progression
Time to disease progression was measured from randomization of Study Phase 2 to the first observation of disease progression according to the Response Evaluation Criteria In Solid Tumors (RECIST) criteria. Disease progression is ≥20% increase in sum of longest diameter of target lesions and/or a new lesion.
Time frame: Phase 2 randomization to measured disease progression up to 24 months
Phase 2 - Median Survival
Time frame: Phase 2 randomization to death as the result of any cause up to 30.0 month
Phase 2 - Percentage of Participants With Complete Response or Partial Response (Response Rate)
Response rate is the percentage of participants with complete response (CR) or partial response (PR), as assessed according to the Response Evaluation Criteria In Solid Tumors (RECIST) guidelines. CR is disappearance of all target and non-target lesions; PR is ≥30% decrease in sum of longest diameter of target lesions. Response rate is calculated as a total number of participants with CR or PR divided by the total number of participants treated multiplied by 100.
Time frame: Phase 2 randomization to the end of the treatment up to 30.0 months
| Milestone | Pemetrexed + Carboplatin (Study Phase 1) | Pemetrexed + Cisplatin (Study Phase 1) | Pemetrexed + Carboplatin (Study Phase 2) | Pemetrexed + Cisplatin (Study Phase 2) |
|---|---|---|---|---|
| Started | 9 | 13 | 46 | 52 |
| Completed | 2 | 7 | 35 | 29 |
| Not completed | 7 | 6 | 11 | 23 |
| Withdrew: Withdrawal by subject | 1 | 2 | 3 | 4 |
| Withdrew: Adverse event | 3 | 0 | 2 | 8 |
| Withdrew: Death | 1 | 2 | 1 | 4 |
| Withdrew: Lack of efficacy | 1 | 0 | 4 | 6 |
| Withdrew: Sponsor decision | 1 | 2 | 1 | 1 |
MTD was defined as a dose at which the occurrence of at least 2 dose-limiting toxicities (DLTs) was observed. DLT was defined as any of the following events occurring during the entire radiation therapy (RT) course, including a 2-week recovery period following completion of RT: Grade 4 neutropenia (\<0.5 x 10\^9 cells per liter) lasting \>7 days, febrile neutropenia; ≥Grade 3 neutropenia with fever \>38.5 degrees Celsius (°C), Grade 4 thrombocytopenia, Grade 3 thrombocytopenia with ≥Grade 2 bleeding, ≥Grade 3 nonhematologic toxicity (excluding nausea, vomiting, and transaminase elevations) and ≥Grade 3 pulmonary or esophageal toxicity (radiation-related pneumonitis or esophagitis).
| milligram/milliliter*minute (mg/mL*min) | Pemetrexed + Carboplatin Treatment Group |
|---|---|
| Phase 1 - Maximum Tolerated Dose (MTD) of Carboplatin | NA |
MTD was defined as a dose at which the occurrence of at least 2 dose-limiting toxicities (DLTs) was observed. DLT was defined as any of the following events occurring during the entire radiation therapy (RT) course, including a 2-week recovery period following completion of RT: Grade 4 neutropenia (\<0.5 x 10\^9 cells per liter) lasting \>7 days, febrile neutropenia; ≥Grade 3 neutropenia with fever \>38.5 degrees Celsius (°C), Grade 4 thrombocytopenia, Grade 3 thrombocytopenia with ≥Grade 2 bleeding, ≥Grade 3 nonhematologic toxicity (excluding nausea, vomiting, and transaminase elevations) and ≥Grade 3 pulmonary or esophageal toxicity (radiation-related pneumonitis or esophagitis).
| milligrams/meter squared (mg/m²) | Pemetrexed + Cisplatin Treatment Group |
|---|---|
| Phase 1 - Maximum Tolerated Dose (MTD) of Cisplatin | NA |
Phase 1 pharmacology toxicity was defined as the number of participants experiencing dose limiting toxicities (DLTs). DLT was defined as any of the following events occurring during the entire radiation therapy (RT) course: Grade 4 neutropenia (\<0.5 x 10\^9 cells per liter) \>7 days, febrile neutropenia, ≥Grade 3 neutropenia with fever \>38.5 degrees Celsius (°C), Grade 4 thrombocytopenia, Grade 3 thrombocytopenia with ≥Grade 2 bleeding, ≥Grade 3 nonhematologic toxicity (excluding nausea, vomiting, and transaminase elevations), and ≥Grade 3 pulmonary or esophageal toxicity (radiation-related pneumonitis or esophagitis). Grade 5 events are the events leading to the death.
| participants | Pemetrexed + Carboplatin Treatment Group | Pemetrexed + Cisplatin Treatment |
|---|---|---|
| Grade 5 Pneumocystis jiroveci pneumonia | 1 | 0 |
| Grade 5 Hemoptysis (pemetrexed+Cisplatin30 mg/m² ) | 0 | 1 |
Response rate is the percentage of participants with complete response (CR) or partial response (PR), as assessed according to the Response Evaluation Criteria In Solid Tumors (RECIST) guidelines. CR is disappearance of all target and non-target lesions; PR is ≥30% decrease in sum of longest diameter of target lesions. Response rate is calculated as a total number of participants with CR or PR divided by the total number of participants treated multiplied by 100.
| percentage of participants | Pemetrexed + Carboplatin Treatment Group | Pemetrexed + Cisplatin Treatment |
|---|---|---|
| Complete Response (CR) | 0 (0.0 to 0.0) | 0 (0.0 to 0.0) |
| Partial Response (PR) | 11.1 (0.28 to 48.25) | 45.5 (16.75 to 76.62) |
Phase 2 pharmacology toxicity was defined as the number of participants who experienced serious adverse events or all other nonserious adverse events during the study. A summary of serious adverse events and other nonserious adverse events is located in the Reported Adverse Events section.
| participants | Pemetrexed + Carboplatin Treatment Group | Pemetrexed + Cisplatin Treatment Group |
|---|---|---|
| Serious Adverse Events | 21 (6.0 to 12.6) | 19 (8.3 to NA) |
| Other Nonserious Adverse Events | 44 | 51 |
Time to disease progression was measured from randomization of Study Phase 2 to the first observation of disease progression according to the Response Evaluation Criteria In Solid Tumors (RECIST) criteria. Disease progression is ≥20% increase in sum of longest diameter of target lesions and/or a new lesion.
| months | Pemetrexed + Carboplatin Treatment Group | Pemetrexed + Cisplatin Treatment Group |
|---|---|---|
| Phase 2 - Time to Progression | 8.8 (6.0 to 12.6) | 13.1 (8.3 to NA) |
| months | Pemetrexed + Carboplatin Treatment Group | Pemetrexed + Cisplatin Treatment Group |
|---|---|---|
| Phase 2 - Median Survival | 18.7 (12.9 to NA) | 27.0 (23.2 to NA) |
Response rate is the percentage of participants with complete response (CR) or partial response (PR), as assessed according to the Response Evaluation Criteria In Solid Tumors (RECIST) guidelines. CR is disappearance of all target and non-target lesions; PR is ≥30% decrease in sum of longest diameter of target lesions. Response rate is calculated as a total number of participants with CR or PR divided by the total number of participants treated multiplied by 100.
| percentage of participants | Pemetrexed + Carboplatin Treatment Group | Pemetrexed + Cisplatin Treatment Group |
|---|---|---|
| Complete Response (CR) | 6.5 (1.4 to 17.9) | 3.8 (0.5 to 13.2) |
| Partial Response (PR) | 45.7 (30.9 to 61.0) | 42.3 (28.7 to 56.8) |
| percentage survival | Pemetrexed + Carboplatin Treatment Group | Pemetrexed + Cisplatin Treatment Group |
|---|---|---|
| Phase 2 - Survival Probability at 2 Years | 45.4 (29.5 to 60.0) | 58.4 (42.6 to 71.3) |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Phase 1: Pemetrexed + Carboplatin | — | 6/9 (66.7%) | 9/9 (100%) |
| Phase 1: Pemetrexed + Cisplatin | — | 5/13 (38.5%) | 10/13 (76.9%) |
| Phase 2: Pemetrexed + Carboplatin | — | 21/46 (45.7%) | 44/46 (95.7%) |
| Phase 2: Pemetrexed + Cisplatin | — | 19/52 (36.5%) | 51/52 (98.1%) |
| Event | Phase 1: Pemetrexed + Carboplatin | Phase 1: Pemetrexed + Cisplatin | Phase 2: Pemetrexed + Carboplatin | Phase 2: Pemetrexed + Cisplatin |
|---|---|---|---|---|
| PyrexiaGeneral disorders | 0/9 | 2/13 | 2/46 | 0/52 |
| NeutropeniaBlood and lymphatic system disorders | 1/9 | 1/13 | 0/46 | 0/52 |
| Pneumocystis jiroveci pneumoniaInfections and infestations | 1/9 | 0/13 | 0/46 | 0/52 |
| PneumoniaInfections and infestations | 1/9 | 1/13 | 2/46 | 2/52 |
| Radiation oesophagitisInjury, poisoning and procedural complications | 1/9 | 0/13 | 0/46 | 2/52 |
| Radiation pneumonitisInjury, poisoning and procedural complications | 1/9 | 0/13 | 1/46 | 1/52 |
| Muscular weaknessMusculoskeletal and connective tissue disorders | 1/9 | 0/13 | 0/46 | 0/52 |
| Neoplasm malignantNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/9 | 0/13 | 0/46 | 0/52 |
| Cerebral infarctionNervous system disorders | 1/9 | 0/13 | 0/46 | 0/52 |
| DehydrationMetabolism and nutrition disorders | 0/9 | 0/13 | 5/46 | 5/52 |
| Event | Phase 1: Pemetrexed + Carboplatin | Phase 1: Pemetrexed + Cisplatin | Phase 2: Pemetrexed + Carboplatin | Phase 2: Pemetrexed + Cisplatin |
|---|---|---|---|---|
| DysphagiaGastrointestinal disorders | 6/9 | 5/13 | 19/46 | 18/52 |
| FatigueGeneral disorders | 6/9 | 7/13 | 26/46 | 27/52 |
| NauseaGastrointestinal disorders | 4/9 | 5/13 | 21/46 | 28/52 |
| AnaemiaBlood and lymphatic system disorders | 4/9 | 5/13 | 14/46 | 16/52 |
| DysgeusiaNervous system disorders | 4/9 | 1/13 | 5/46 | 5/52 |
| OesophagitisGastrointestinal disorders | 1/9 | 1/13 | 19/46 | 21/52 |
| NeutropeniaBlood and lymphatic system disorders | 2/9 | 1/13 | 16/46 | 12/52 |
| StomatitisGastrointestinal disorders | 3/9 | 1/13 | 2/46 | 3/52 |
| PyrexiaGeneral disorders | 3/9 | 1/13 | 4/46 | 5/52 |
| InsomniaPsychiatric disorders | 3/9 | 1/13 | 11/46 | 9/52 |
| Age Continuous(Years) | Pemetrexed + Carboplatin (Study Phase 1) | Pemetrexed + Cisplatin (Study Phase 1) | Pemetrexed + Carboplatin (Study Phase 2) | Pemetrexed + Cisplatin (Study Phase 2) | Total |
|---|---|---|---|---|---|
| Mean | 61.9 ± 8.70 | 61.0 ± 11.66 | 63.6 ± 9.92 | 64.1 ± 9.44 | 63.4 ± 9.77 |
| Sex: Female, Male(Participants) | Pemetrexed + Carboplatin (Study Phase 1) | Pemetrexed + Cisplatin (Study Phase 1) | Pemetrexed + Carboplatin (Study Phase 2) | Pemetrexed + Cisplatin (Study Phase 2) | Total |
|---|---|---|---|---|---|
| Female | 2 | 4 | 16 | 21 | 43 |
| Male | 7 | 9 | 30 | 31 | 77 |
| Race/Ethnicity, Customized(participants) | Pemetrexed + Carboplatin (Study Phase 1) | Pemetrexed + Cisplatin (Study Phase 1) | Pemetrexed + Carboplatin (Study Phase 2) | Pemetrexed + Cisplatin (Study Phase 2) | Total |
|---|---|---|---|---|---|
| Caucasian | 8 ± 73.3 | 7 | 36 | 37 | 88 |
| African | 1 ± 11.7 | 3 | 5 | 5 | 14 |
| Hispanic | 0 ± 1.7 | 1 | 1 | 0 | 2 |
| East Asian | 0 ± 1.7 | 0 | 1 | 1 | 2 |
| West Asian (Indian sub continent | 0 ± 11.7 | 2 | 3 | 9 | 14 |
| Region of Enrollment(participants) | Pemetrexed + Carboplatin (Study Phase 1) | Pemetrexed + Cisplatin (Study Phase 1) | Pemetrexed + Carboplatin (Study Phase 2) | Pemetrexed + Cisplatin (Study Phase 2) | Total |
|---|---|---|---|---|---|
| United States | 9 | 13 | 43 | 43 | 108 |
| India | 0 | 0 | 3 | 9 | 12 |
The record gives a start of May 2007, a primary completion of Oct 2011 and a completion of Oct 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2012, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Cisplatin · Carboplatin
Carcinoma, Non-Small-Cell Lung →